Aptamer Sciences Inc — Investor Relations & Filings
Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 주식등의대량보유상황보고서(약식) | 2026-04-22 | Korean | |
| 주식등의대량보유상황보고서(약식) | 2026-04-17 | Korean | |
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-04-17 | Korean | |
| 증권발행결과(자율공시) | 2026-04-14 | Korean | |
| 증권발행결과(자율공시) | 2026-04-09 | Korean | |
| [기재정정]주요사항보고서(유상증자결정) | 2026-04-06 | Korean |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 35195861 | 주식등의대량보유상황보고서(약식) | 2026-04-22 | Korean | ||
| 34653070 | 주식등의대량보유상황보고서(약식) | 2026-04-17 | Korean | ||
| 34653005 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-04-17 | Korean | ||
| 34472169 | 증권발행결과(자율공시) | 2026-04-14 | Korean | ||
| 33874292 | 증권발행결과(자율공시) | 2026-04-09 | Korean | ||
| 33596305 | [기재정정]주요사항보고서(유상증자결정) | 2026-04-06 | Korean | ||
| 33134757 | [기재정정]주요사항보고서(유상증자결정) | 2026-04-01 | Korean | ||
| 33134728 | [기재정정]주요사항보고서(타법인주식및출자증권양수결정) | 2026-04-01 | Korean | ||
| 33038933 | 주요사항보고서(타법인주식및출자증권양수결정) | 2026-03-25 | Korean | ||
| 33011746 | 정기주주총회결과 | 2026-03-23 | Korean | ||
| 32971183 | [기재정정]주요사항보고서(유상증자결정) | 2026-03-18 | Korean | ||
| 32971145 | [기재정정]주요사항보고서(유상증자결정) | 2026-03-18 | Korean | ||
| 32941613 | 사업보고서 (2025.12) | 2026-03-13 | Korean | ||
| 32940925 | 감사보고서제출 | 2026-03-13 | Korean | ||
| 32907694 | 매출액또는손익구조30%(대규모법인은15%)이상변동 | 2026-03-06 | Korean | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Adaptogenics Health Corp.
Formulates and distributes functional mushroom and adaptoge…
|
ADPT | CA | Manufacturing |
|
Adastra Holdings
Manufacturer and supplier of ethnobotanical and processed c…
|
XTRX | CA | Manufacturing |
|
ADBIOTECH Co.,Ltd.
Develops IgY-based immune antibodies as alternatives to vac…
|
179530 | KR | Manufacturing |
|
ADC Therapeutics SA
Commercial-stage biotech developing antibody-drug conjugate…
|
ADCT | US | Manufacturing |
|
Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators f…
|
ADXN | CH | Manufacturing |
|
Adeshwar Meditex Limited
Manufacturer and exporter of medical disposables, surgical …
|
543309 | IN | Manufacturing |
|
ADIAL PHARMACEUTICALS, INC.
A clinical-stage biopharma developing genetically targeted …
|
ADIL | US | Manufacturing |
|
Adicet Bio, Inc.
Develops allogeneic gamma delta T cell therapies for cancer…
|
ACET | US | Manufacturing |
|
ADIMMUNE CORPORATION
Develops and manufactures human vaccines and biologics for …
|
4142 | TW | Manufacturing |
|
Adlai Nortye Ltd.
A clinical-stage biopharma firm developing cancer immunothe…
|
ANL | KY | Manufacturing |
Aptamer Sciences Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/15099/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=15099 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=15099 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=15099 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 15099}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aptamer Sciences Inc (id: 15099)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.